- Home
- YQ vs VERU Comparison
YQ vs VERU Comparison
Compare YQ & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YQ | VERU |
|---|---|---|
| Founded | 2012 | 1971 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.3M | 39.8M |
| IPO Year | 2020 | 1990 |
Fundamental Metrics
Financial Performance| Metric | YQ | VERU |
|---|---|---|
| Price | $4.78 | $2.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 19.7K | ★ 120.4K |
| Earning Date | 12-09-2025 | 12-16-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $20,003,071.00 | $16,886,419.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 337.24 |
| 52 Week Low | $1.26 | $2.11 |
| 52 Week High | $6.45 | $14.20 |
Technical Indicators
Market Signals| Indicator | YQ | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 43.03 | 47.95 |
| Support Level | $4.50 | $2.33 |
| Resistance Level | $5.23 | $2.51 |
| Average True Range (ATR) | 0.32 | 0.17 |
| MACD | -0.03 | 0.06 |
| Stochastic Oscillator | 13.33 | 98.04 |
Price Performance
Historical ComparisonAbout YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.